Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash-to-Debt 3.73
NAS:ACRX's Cash-to-Debt is ranked higher than
57% of the 291 Companies
in the Global Medical Devices industry.

( Industry Median: 2.43 vs. NAS:ACRX: 3.73 )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:ACRX' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.31  Med: 3.03 Max: 7.22
Current: 3.73
0.31
7.22
Equity-to-Asset -0.05
NAS:ACRX's Equity-to-Asset is ranked lower than
92% of the 269 Companies
in the Global Medical Devices industry.

( Industry Median: 0.62 vs. NAS:ACRX: -0.05 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:ACRX' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.05  Med: 0.48 Max: 0.67
Current: -0.05
-0.05
0.67
Piotroski F-Score: 2
Altman Z-Score: -2.58
Beneish M-Score: -1.19
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % -184.12
NAS:ACRX's Operating Margin % is ranked lower than
82% of the 273 Companies
in the Global Medical Devices industry.

( Industry Median: 2.84 vs. NAS:ACRX: -184.12 )
Ranked among companies with meaningful Operating Margin % only.
NAS:ACRX' s Operating Margin % Range Over the Past 10 Years
Min: -1805.22  Med: -452.89 Max: -22.6
Current: -184.12
-1805.22
-22.6
Net Margin % -248.64
NAS:ACRX's Net Margin % is ranked lower than
83% of the 273 Companies
in the Global Medical Devices industry.

( Industry Median: 2.18 vs. NAS:ACRX: -248.64 )
Ranked among companies with meaningful Net Margin % only.
NAS:ACRX' s Net Margin % Range Over the Past 10 Years
Min: -1875.09  Med: -443.98 Max: -79.4
Current: -248.64
-1875.09
-79.4
ROE % -317.38
NAS:ACRX's ROE % is ranked lower than
97% of the 265 Companies
in the Global Medical Devices industry.

( Industry Median: 2.23 vs. NAS:ACRX: -317.38 )
Ranked among companies with meaningful ROE % only.
NAS:ACRX' s ROE % Range Over the Past 10 Years
Min: -317.38  Med: -61.17 Max: -43.78
Current: -317.38
-317.38
-43.78
ROA % -37.95
NAS:ACRX's ROA % is ranked lower than
73% of the 294 Companies
in the Global Medical Devices industry.

( Industry Median: 0.21 vs. NAS:ACRX: -37.95 )
Ranked among companies with meaningful ROA % only.
NAS:ACRX' s ROA % Range Over the Past 10 Years
Min: -134.55  Med: -63.33 Max: -22.78
Current: -37.95
-134.55
-22.78
ROC (Joel Greenblatt) % -340.11
NAS:ACRX's ROC (Joel Greenblatt) % is ranked lower than
77% of the 290 Companies
in the Global Medical Devices industry.

( Industry Median: 4.32 vs. NAS:ACRX: -340.11 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:ACRX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -1434.7  Med: -878.27 Max: -173.98
Current: -340.11
-1434.7
-173.98
3-Year Revenue Growth Rate -19.80
NAS:ACRX's 3-Year Revenue Growth Rate is ranked lower than
83% of the 229 Companies
in the Global Medical Devices industry.

( Industry Median: 4.70 vs. NAS:ACRX: -19.80 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NAS:ACRX' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -9.9 Max: 58.9
Current: -19.8
0
58.9
3-Year EBITDA Growth Rate 61.10
NAS:ACRX's 3-Year EBITDA Growth Rate is ranked higher than
91% of the 200 Companies
in the Global Medical Devices industry.

( Industry Median: 5.60 vs. NAS:ACRX: 61.10 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NAS:ACRX' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: -50.2 Max: 61.1
Current: 61.1
0
61.1
3-Year EPS without NRI Growth Rate 17.20
NAS:ACRX's 3-Year EPS without NRI Growth Rate is ranked higher than
69% of the 197 Companies
in the Global Medical Devices industry.

( Industry Median: 2.40 vs. NAS:ACRX: 17.20 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NAS:ACRX' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: -45.7 Max: 17.2
Current: 17.2
0
17.2
GuruFocus has detected 6 Warning Signs with AcelRx Pharmaceuticals Inc $NAS:ACRX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:ACRX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

ACRX Guru Trades in Q2 2015

Paul Tudor Jones 24,100 sh (-54.18%)
» More
Q3 2015

ACRX Guru Trades in Q3 2015

Paul Tudor Jones Sold Out
» More
Q2 2016

ACRX Guru Trades in Q2 2016

Jim Simons 21,100 sh (New)
» More
Q3 2016

ACRX Guru Trades in Q3 2016

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with ACRX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Devices » Medical Devices    NAICS: 339112    SIC: 3829
Compare:NAS:IRIX, NAS:NVCN, NAS:PAVM, NAS:FONR, NAS:CGNT, NAS:DRAD, NAS:MSON, NAS:OBLN, NAS:IRMD, NAS:SPNE, OTCPK:IPDQF, NAS:EDAP, OTCPK:PHMZF, NAS:EYES, NAS:NVTR, NAS:SRTS, NAS:RTIX, NAS:SPAN, OTCPK:AVMXF, AMEX:CVRS » details
Traded in other countries:R5X.Germany,
AcelRx Pharmaceuticals Inc is a specialty pharmaceutical company. The Company is engaged in the development and commercialization of therapies for the treatment of acute pain.

AcelRx Pharmaceuticals Inc was was incorporated in Delaware on July 13, 2005 as SuRx, Inc. In January 2006, the Company has changed its name to AcelRx Pharmaceuticals, Inc. It is a development stage company. The Company is a specialty pharmaceutical company engaged in the development and commercialization of therapies for the treatment of acute and breakthrough pain. The Company's main product candidate, Zalviso, formerly known as the Sufentanil NanoTab PCA System, or ARX-01, is currently under review by the FDA for marketing approval, and is designed to improve the management of moderate-to-severe acute pain in patients in the hospital setting. In addition, in December 2013, the Company entered into a collaboration agreement with Grünenthal for the commercialization of Zalviso in Europe and Australia. Its sufentanil-based products are subject to extensive regulation by the DEA, due to their status as scheduled drugs. Its registered trademarks include ACELRX and NANOTAB.

Ratios

vs
industry
vs
history
PS Ratio 7.96
ACRX's PS Ratio is ranked lower than
78% of the 329 Companies
in the Global Medical Devices industry.

( Industry Median: 3.34 vs. ACRX: 7.96 )
Ranked among companies with meaningful PS Ratio only.
ACRX' s PS Ratio Range Over the Past 10 Years
Min: 4.69  Med: 31.17 Max: 2370
Current: 7.96
4.69
2370
Current Ratio 8.74
ACRX's Current Ratio is ranked higher than
94% of the 287 Companies
in the Global Medical Devices industry.

( Industry Median: 2.28 vs. ACRX: 8.74 )
Ranked among companies with meaningful Current Ratio only.
ACRX' s Current Ratio Range Over the Past 10 Years
Min: 0.43  Med: 4.86 Max: 15.22
Current: 8.74
0.43
15.22
Quick Ratio 8.53
ACRX's Quick Ratio is ranked higher than
95% of the 287 Companies
in the Global Medical Devices industry.

( Industry Median: 1.65 vs. ACRX: 8.53 )
Ranked among companies with meaningful Quick Ratio only.
ACRX' s Quick Ratio Range Over the Past 10 Years
Min: 0.43  Med: 4.86 Max: 15.22
Current: 8.53
0.43
15.22
Days Inventory 37.00
ACRX's Days Inventory is ranked higher than
90% of the 257 Companies
in the Global Medical Devices industry.

( Industry Median: 124.59 vs. ACRX: 37.00 )
Ranked among companies with meaningful Days Inventory only.
ACRX' s Days Inventory Range Over the Past 10 Years
Min: 37  Med: 43.44 Max: 48.05
Current: 37
37
48.05
Days Sales Outstanding 122.66
ACRX's Days Sales Outstanding is ranked lower than
86% of the 243 Companies
in the Global Medical Devices industry.

( Industry Median: 67.79 vs. ACRX: 122.66 )
Ranked among companies with meaningful Days Sales Outstanding only.
ACRX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 62.26  Med: 92.46 Max: 122.66
Current: 122.66
62.26
122.66
Days Payable 46.18
ACRX's Days Payable is ranked lower than
61% of the 229 Companies
in the Global Medical Devices industry.

( Industry Median: 57.49 vs. ACRX: 46.18 )
Ranked among companies with meaningful Days Payable only.
ACRX' s Days Payable Range Over the Past 10 Years
Min: 46.18  Med: 184.04 Max: 321.9
Current: 46.18
46.18
321.9

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -1.70
ACRX's 3-Year Average Share Buyback Ratio is ranked higher than
61% of the 212 Companies
in the Global Medical Devices industry.

( Industry Median: -3.60 vs. ACRX: -1.70 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ACRX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -303.2  Med: -18.8 Max: 0
Current: -1.7
-303.2
0

Valuation & Return

vs
industry
vs
history
Price-to-Median-PS-Value 0.26
ACRX's Price-to-Median-PS-Value is ranked higher than
93% of the 287 Companies
in the Global Medical Devices industry.

( Industry Median: 1.10 vs. ACRX: 0.26 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ACRX' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.21  Med: 0.75 Max: 1.79
Current: 0.26
0.21
1.79
Earnings Yield (Greenblatt) % -39.02
ACRX's Earnings Yield (Greenblatt) % is ranked lower than
84% of the 415 Companies
in the Global Medical Devices industry.

( Industry Median: 0.86 vs. ACRX: -39.02 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ACRX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -45.52  Med: 3.75 Max: 9.1
Current: -39.02
-45.52
9.1

More Statistics

Revenue (TTM) (Mil) $17.36
EPS (TTM) $ -0.95
Beta2.69
Short Percentage of Float13.33%
52-Week Range $2.40 - 4.08
Shares Outstanding (Mil)45.34

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 11 40 83
EPS ($) -1.12 -0.59 0.09
EPS without NRI ($) -1.12 -0.59 0.09
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for ACRX

Headlines

Articles On GuruFocus.com
Weekly CFO Buys Highlight: BK, MWW, BLD, ACRX, PSEC Sep 12 2011 

More From Other Websites
7:02 am AcelRx announces that the European Medicines Agency has notified the company that the ARX-04... Mar 28 2017
European Medicines Agency Begins Evaluation of Marketing Application for Sublingual Sufentanil 30... Mar 28 2017
ETFs with exposure to AcelRx Pharmaceuticals, Inc. : March 27, 2017 Mar 27 2017
AcelRx Pharmaceuticals, Inc. :ACRX-US: Earnings Analysis: Q4, 2016 By the Numbers : March 20, 2017 Mar 20 2017
AcelRx Pharmaceuticals to Participate at Three Upcoming Investor Events in March and April Mar 17 2017
AcelRx Pharmaceuticals, Inc. to Present at The MicroCap Conference on April 4th in New York City at... Mar 16 2017
AcelRx Pharmaceuticals Presents Efficacy and Pharmacokinetics of DSUVIA™ at Upcoming Congresses Mar 16 2017
AcelRx Pharmaceuticals, Inc. :ACRX-US: Earnings Analysis: 2016 By the Numbers : March 14, 2017 Mar 14 2017
ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial... Mar 10 2017
ACELRX PHARMACEUTICALS INC Financials Mar 08 2017
ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Mar 07 2017
ACELRX PHARMACEUTICALS INC Files SEC form 10-K, Annual Report Mar 03 2017
AcelRx Pharmaceuticals reports 4Q loss Mar 02 2017
AcelRx Pharmaceuticals reports 4Q loss Mar 02 2017
AcelRx Pharmaceuticals Reports Fourth Quarter and Year End 2016 Financial Results Mar 02 2017
Q4 2016 AcelRx Pharmaceuticals Inc Earnings Release - After Market Close Mar 02 2017
AcelRx Pharmaceuticals to Participate at Two Upcoming Investor Events in March Mar 01 2017
AcelRx Pharmaceuticals' New Drug Application for DSUVIA Accepted for Filing with PDUFA Date of... Feb 27 2017
AcelRx Pharmaceuticals to Hold Annual 2016 Financial Results Conference Call and Webcast on... Feb 23 2017
ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers Feb 16 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)